{"id":"W3107453141","doi":"10.1136/esmoopen-2020-001079","title":"Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial","year":2020,"lang":"en","type":"article","venue":"ESMO Open","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":522,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"National Cancer Institute; Bristol-Myers Squibb Canada; National Institutes of Health; Memorial Sloan-Kettering Cancer Center","keywords":"Sunitinib; Medicine; Ipilimumab; Nivolumab; Renal cell carcinoma; Internal medicine; Gastroenterology; Oncology; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001684032,0.0003784766,0.001142072,0.00006145013,0.0001425077,0.00002177509,0.0004861975,0.0001194203,0.0003127932],"category_scores_gemma":[0.0001393429,0.0002598503,0.0005741235,0.0002818698,0.0001274424,0.0001114393,0.0002182658,0.0001173067,0.00001330398],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003933354,"about_ca_system_score_gemma":0.0005699875,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007365238,"about_ca_topic_score_gemma":0.0002492895,"domain_scores_codex":[0.9977703,0.00009710244,0.0007821237,0.0005390096,0.0004200525,0.0003914079],"domain_scores_gemma":[0.9979939,0.0002356165,0.0004882688,0.0008109944,0.0002150435,0.0002561071],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9711877,0.003442656,0.000164795,0.0003599974,0.0006392266,0.0001058524,0.003618451,0.0001509626,0.009708098,0.0001821506,0.00116017,0.009279929],"study_design_scores_gemma":[0.6368122,0.03132326,0.0007548517,0.00006657904,0.001038785,0.00000555148,0.0006242759,0.0003831888,0.3234068,0.00002492082,0.005358638,0.0002009297],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9854496,0.0002383781,0.0000418072,0.0009828021,0.0005797258,0.007018694,0.0002781296,0.00002754325,0.005383386],"genre_scores_gemma":[0.995093,0.00005062638,0.0009154804,0.0000585675,0.0002711157,0.0005003103,0.0002951396,0.00006444618,0.002751349],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3343755,"threshold_uncertainty_score":0.9999854,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.086461553476601,"score_gpt":0.333877590462352,"score_spread":0.247416036985751,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}